Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.760
+0.180 (5.03%)
At close: Jun 27, 2025, 4:00 PM
3.740
-0.020 (-0.53%)
After-hours: Jun 27, 2025, 4:04 PM EDT
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 2.23M CHF in the twelve months ending March 31, 2025, down -66.82% year-over-year. In the year 2024, Molecular Partners AG had annual revenue of 4.97M, down -29.38%.
Revenue (ttm)
2.23M CHF
Revenue Growth
-66.82%
P/S Ratio
55.41
Revenue / Employee
14,082 CHF
Employees
159
Market Cap
139.92M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MOLN News
- 5 days ago - Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - GlobeNewsWire
- 18 days ago - Molecular Partners to cut workforce by a quarter - Reuters
- 18 days ago - Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway - GlobeNewsWire
- 5 weeks ago - Molecular Partners to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 - GlobeNewsWire
- 2 months ago - Molecular Partners Announces all Board Proposals Approved at Annual General Meeting - GlobeNewsWire
- 3 months ago - Molecular Partners to hold three poster presentations at AACR 2025 - GlobeNewsWire
- 3 months ago - Molecular Partners Publishes Invitation to Annual General Meeting 2025 - GlobeNewsWire